Company Profile
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company provides the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas.
Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction.
It also develops VV116, a RNA-dependent RNA polymerase inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection COVID-19 infections.
Its portfolio also includes TPN102, a novel antiepileptic drug, which is in Phase I clinical trial for the treatment of epilepsy, VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia, and VV261, a novel nucleoside prodrug, which is in Phase I clinical trial for chikungunya, coronaviruses, influenza, and arena virus.
Additionally, it develops VV913, a novel investigational drug candidate for premature ejaculation. Its portfolio also includes VV147 for the treatment of major depressive disorder, and VV207 for the treatment of adenovirus infection. Incorporated in 2013, the company is headquartered in Suzhou, China.